Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2311944rdf:typepubmed:Citationlld:pubmed
pubmed-article:2311944lifeskim:mentionsumls-concept:C0001563lld:lifeskim
pubmed-article:2311944lifeskim:mentionsumls-concept:C0035608lld:lifeskim
pubmed-article:2311944lifeskim:mentionsumls-concept:C1522223lld:lifeskim
pubmed-article:2311944lifeskim:mentionsumls-concept:C0205321lld:lifeskim
pubmed-article:2311944pubmed:issue1lld:pubmed
pubmed-article:2311944pubmed:dateCreated1990-4-26lld:pubmed
pubmed-article:2311944pubmed:abstractTextRifampin, the most potent anti-staphylococcal drug known, was examined for its penetration into the aqueous and vitreous of rabbits after a single oral dose of 150 mg, 300 mg, or 600 mg. Maximum levels after the 150 mg dose were achieved at 4 h and were 4.2 micrograms/ml in the aqueous and 2.2 micrograms/ml in the vitreous. After the 300 mg dose, maximum levels were also achieved at 4 h, and were 5.0 micrograms/ml in the aqueous and 2.6 micrograms/ml in the vitreous. The 600 mg dose produced maximum levels at 6 h after administration, with 20.0 micrograms/ml in the aqueous and 15.2 micrograms/ml in the vitreous. These levels exceed the minimum inhibitory concentration for many microorganisms and suggest additional investigation into possible applications of systemic rifampin in the prophylaxis and treatment of bacterial endophthalmitis.lld:pubmed
pubmed-article:2311944pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2311944pubmed:languageenglld:pubmed
pubmed-article:2311944pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2311944pubmed:citationSubsetIMlld:pubmed
pubmed-article:2311944pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2311944pubmed:statusMEDLINElld:pubmed
pubmed-article:2311944pubmed:issn0721-832Xlld:pubmed
pubmed-article:2311944pubmed:authorpubmed-author:KenyonK RKRlld:pubmed
pubmed-article:2311944pubmed:authorpubmed-author:WongK WKWlld:pubmed
pubmed-article:2311944pubmed:authorpubmed-author:D'AmicoD JDJlld:pubmed
pubmed-article:2311944pubmed:authorpubmed-author:BakerP APAlld:pubmed
pubmed-article:2311944pubmed:authorpubmed-author:OumB SBSlld:pubmed
pubmed-article:2311944pubmed:issnTypePrintlld:pubmed
pubmed-article:2311944pubmed:volume228lld:pubmed
pubmed-article:2311944pubmed:ownerNLMlld:pubmed
pubmed-article:2311944pubmed:authorsCompleteYlld:pubmed
pubmed-article:2311944pubmed:pagination40-3lld:pubmed
pubmed-article:2311944pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2311944pubmed:meshHeadingpubmed-meshheading:2311944-...lld:pubmed
pubmed-article:2311944pubmed:meshHeadingpubmed-meshheading:2311944-...lld:pubmed
pubmed-article:2311944pubmed:meshHeadingpubmed-meshheading:2311944-...lld:pubmed
pubmed-article:2311944pubmed:meshHeadingpubmed-meshheading:2311944-...lld:pubmed
pubmed-article:2311944pubmed:meshHeadingpubmed-meshheading:2311944-...lld:pubmed
pubmed-article:2311944pubmed:meshHeadingpubmed-meshheading:2311944-...lld:pubmed
pubmed-article:2311944pubmed:meshHeadingpubmed-meshheading:2311944-...lld:pubmed
pubmed-article:2311944pubmed:year1990lld:pubmed
pubmed-article:2311944pubmed:articleTitleIntraocular penetration of rifampin after oral administration.lld:pubmed
pubmed-article:2311944pubmed:affiliationHowe Laboratory of Ophthalmology, Harvard Medical School, Boston, MA.lld:pubmed
pubmed-article:2311944pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2311944pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed